Aaron Thomson

Steven Silver

- On **September 3, 2025**, bioAffinity Technologies, Inc. announced that its **CyPath® Lung** diagnostic test was featured in **U.S. Medicine Magazine**, highlighting its potential to improve lung cancer detection and lower costs for the Department of Veterans Affairs (VA).  **[1712762_0001641172-25-026403_ex99-1.htm:0]** **[1712762_0001641172-25-026403_form8-k.htm:1]** 
- Research published in the Journal of Health Economics and Outcomes Research (JHEOR) indicated that integrating CyPath® Lung into the standard of care could have resulted in savings of nearly **$895 million for private payers** and **$379 million for Medicare** in 2022, primarily by reducing follow-up diagnostic assessments and procedures.  **[1712762_0001641172-25-026403_ex99-1.htm:0]** 
- Clinical study results demonstrated that CyPath® Lung achieved **92% sensitivity**, **87% specificity**, and **88% accuracy** in detecting lung cancer in high-risk patients with small lung nodules (less than 20 mm).  **[1712762_0001641172-25-026403_ex99-1.htm:0]** **[1712762_0001641172-25-026403_ex99-1.htm:1]**

bioAffinity Technologies (BIAF)